Cryoport (CYRX) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $57.6 million, up 1% year-over-year, with sequential growth across all business lines and commercial Cell & Gene Therapy revenue up 51% year-over-year and 20% sequentially.

• Supported a record 684 global clinical trials as of June 30, 2024, including 76 in Phase 3 and 14 commercial therapies.

• Services accounted for 66% of total revenue in Q2 2024, up from 62% in Q2 2023.

• Cost reduction initiatives are expected to yield $22 million in annualized savings and a return to positive adjusted EBITDA in 2025.

• Net loss for Q2 2024 was $78.0 million, primarily due to a $63.8 million impairment loss; excluding this, net loss was $14.2 million.

Financial highlights

• Life Sciences Services revenue for Q2 2024 was $38.0 million, up 8.1% year-over-year; Life Sciences Products revenue was $19.6 million, down 10.4% year-over-year but up 9.8% sequentially.

• Gross margin for Q2 2024 was 43.7%, slightly up from 43.4% in Q2 2023.

• Adjusted EBITDA for Q2 2024 was negative $3.8 million, compared to negative $1.3 million in Q2 2023.

• Cash, cash equivalents, and short-term investments totaled $427.1 million as of June 30, 2024.

• Net loss per share for Q2 2024 was $1.62, compared to $0.42 in Q2 2023.

Outlook and guidance

• Full-year 2024 revenue guidance is $225–$235 million, with sequential improvements anticipated in Life Sciences Services and continued softness in Life Sciences Products.

• Cost reduction and capital realignment measures are expected to be fully implemented by end of 2024, supporting profitable growth and positive adjusted EBITDA in 2025.

• Management expects a return to year-over-year revenue growth in the second half of 2024.

• Expecting stable MVE revenue (~$18 million per quarter) for the remainder of 2024, with growth resuming in 2025.